Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit (2016 - 2025)

Historic Gross Profit for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $134.4 million.

  • Ani Pharmaceuticals' Gross Profit rose 5766.92% to $134.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year increase of 5222.82%. This contributed to the annual value of $364.2 million for FY2024, which is 1928.02% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Gross Profit stood at $134.4 million, which was up 5766.92% from $136.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Gross Profit registered a high of $136.8 million during Q2 2025, and its lowest value of -$8.8 million during Q1 2021.
  • In the last 5 years, Ani Pharmaceuticals' Gross Profit had a median value of $74.3 million in 2023 and averaged $69.2 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Gross Profit plummeted by 13140.87% in 2021 and then soared by 44383.61% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Gross Profit (Quarter) stood at $27.0 million in 2021, then skyrocketed by 114.22% to $57.9 million in 2022, then soared by 35.11% to $78.2 million in 2023, then soared by 40.98% to $110.3 million in 2024, then increased by 21.88% to $134.4 million in 2025.
  • Its last three reported values are $134.4 million in Q3 2025, $136.8 million for Q2 2025, and $124.1 million during Q1 2025.